Actions of ethnobotanically selected Cree anti-diabetic plants on human cytochrome P450 isoforms and flavin-containing monooxygenase 3

Journal of Ethnopharmacology

Volumn 126, Issue 1, 2009, Pages 119-126

  Tam, Teresa W ^a   Liu, Rui ^a   Arnason, John T ^a   Krantis, Anthony ^a   Staines, William A ^a   Haddad, Pierre S ^b   Foster, Brian C ^a,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c HEALTH CANADA   (Canada)

Author keywords

Cree; Cytochrome P450 inhibition; Diabetes; FMO3; Natural health products

Indexed keywords

ABIES BALSAMEA EXTRACT; ALDER INCANA EXTRACT; ANTIDIABETIC AGENT; AROMATASE; BLACK SPRUCE EXTRACT; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; DIMETHYLANILINE MONOOXYGENASE; GAULTHERIA HISPIDULA EXTRACT; ISOPROTEIN; JUNIPERUS EXTRACT; KALMIA ANGUSTIFOLIA EXTRACT; LARIX LARICINA EXTRACT; LYCOPODIUM EXTRACT; PINUS BANKSIANA EXTRACT; PLANT EXTRACT; RHODODENDRON GROENLANDICUM EXTRACT; RHODODENDRON TOMENTOSUM EXTRACT; SARRACENIA PURPUREA EXTRACT; SORBUS DECORA EXTRACT; UNCLASSIFIED DRUG; UNINDEXED DRUG; WHITE SPRUCE EXTRACT;

ABIES; ABIES BALSAMEA; ALDER; ALDER INCANA; ARTICLE; ASPEN; BLACK SPRUCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME INHIBITION; ETHNOBOTANY; FLUOROMETRY; GAULTHERIA; GAULTHERIA HISPIDULA; JUNIPERUS; KALMIA ANGUSTIFOLIA; LARIX; LARIX LARICINA; LYCOPODIUM; MEDICINAL PLANT; PINE; PINUS BANKSIANA; POPULUS BALSAMIFERA; RHODODENDRON; RHODODENDRON GROENLANDICUM; RHODODENDRON TOMENTOSUM; SALIX PLANIFOLIA; SARRACENIA PURPUREA; SORBUS; SORBUS DECORA; TRADITIONAL MEDICINE; VACCINIUM; VACCINIUM VITIS; WHITE SPRUCE; WILLOW;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYPOGLYCEMIC AGENTS; INDIANS, NORTH AMERICAN; ISOENZYMES; MEDICINE, TRADITIONAL; OXYGENASES; PLANT EXTRACTS;

KALMIA ANGUSTIFOLIA; RHODODENDRON GROENLANDICUM; SORBUS DECORA;

EID: 70349774222     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jep.2009.07.036     Document Type: Article

References (48)

1. Andrew Williams J., Ring B.J., Cantrell V.E., Jones D.R., Eckstein J., Ruterbories K., et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metabolism and Disposition 30 (2002) 883-891
2. Anzenbacher P., and Anzenbacherová E. Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Life Sciences 58 (2001) 737-747
3. Anzenbacher P., Anzenbacherová E., Lange R., Skopalík J., and Otyepka M. Active sites of cytochromes P450: what are they like?. Acta Chimica Slovenica 55 (2008) 63-66
4. Bailey D.G., Spence J.D., Munoz C., and Arnold J.M.O. Interaction of citrus juices with felodipine and nifedipine. Lancet 337 (1991) 268-269
5. Ball S.E., Ahern D., Scatina J., and Kao J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. British Journal of Clinical Pharmacology 43 (1997) 619-626
6. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circulation Research 87 (2000) 840-844
7. Cashman J.R. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Current Drug Metabolism 1 (2000) 181-191
8. Castberg I., Helle J., and Aamo T.O. Prolonged pharmacokinetic drug interaction between terbinafine and amitriptyline. Therapeutic Drug Monitoring 27 (2005) 680-682
9. Cederbaum A.I. CYP2E1-biochemical and toxicological aspects and role in alcohol-induced liver injury. Mount Sinai Journal of Medicine 73 (2006) 657-672
10. Chang G.W.M., and Kam P.C.A. The physiological and pharmacological roles of cytochrome P450 isoenzymes. Anaesthesia 54 (1999) 42-50
11. Cornelis M.C., El-Sohemy A., Kabagambe E.K., and Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. Journal of the American Medical Association 295 (2006) 1135-1141
12. Flanagan D. Understanding the grapefruit-drug interaction. General Dentistry 53 (2005) 282-285
13. Foster B.C., Arnason J.T., and Briggs C.J. Natural health products and drug disposition. Annual Review of Pharmacology and Toxicology 45 (2005) 203-226
14. Fowler M.W. Plants, medicines and man. Journal of the Science of Food and Agriculture 86 (2006) 1797-1804
15. Ghosal A., Hapangama N., Yuan Y., Lu X., Horne D., Patrick J.E., et al. Rapid determination of enzyme activities of recombinant human cytochromes P450, human liver microsomes and hepatocytes. Biopharmaceutics and Drug Disposition 24 (2003) 375-384
16. Guengerich F.P. Cytochromes P450, drugs, and diseases. Molecular Interventions 3 (2003) 194-204
17. Guengerich F.P. Cytochrome P450 and chemical toxicology. Chemical Research in Toxicology 21 (2008) 70-83
18. Haehner B.D., Gorski J.C., Vandenbranden M., Wrighton S.A., Janardan S.K., Watkins P.B., et al. Bimodal distribution of renal cytochrome P450 3A activity in humans. Molecular Pharmacology 50 (1996) 52-59
19. Harbilas D., Martineau L.C., Harris C.S., Adeyiwola-Spoor D.C.A., Saleem A., Lambert J., et al. Evaluation of the anti-diabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II. Canadian Journal of Physiology and Pharmacology 87 (2009) 479-492
20. Kaneto H., Kajimoto Y., Miyagawa J., Matsuoka T., Fujitani Y., Umayahara Y., et al. Beneficial effects of antioxidants in diabetes: possible protection of pancreatic β-cells against glucose toxicity. Diabetes 48 (1999) 2398-2406
21. Kenworthy K.E., Bloomer J.C., Clarke S.E., and Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology 48 (1999) 716-727
22. Kenworthy K.E., Clarke S.E., Andrews J., and Houston J.B. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metabolism and Disposition 29 (2001) 1644-1651
23. Kirchheiner J., Roots I., Goldammer M., Rosenkranz B., and Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical Pharmacokinetics 44 (2005) 1209-1225
24. Kuzmina E., and Lejeune P. Cree Diabetes Information System (CDIS) 2006 Annual Update (2006), Cree Board of Health and Social Services of James Bay, Quebec
25. Leduc C., Coonishish J., Haddad P.S., and Cuerrier A. Plants used by the Cree nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany. Journal of Ethnopharmacology 105 (2006) 55-63
26. Lewis D.F.V. Human cytochromes P450 associated with phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Current Medicinal Chemistry 10 (2003) 1955-1972
27. Lewis D.F.V. 57 varieties: the human cytochromes P450. Pharmacogenomics 5 (2004) 305-318
28. Lewis D.F.V., Ito Y., and Goldfarb P.S. Cytochrome P450 structures and their substrate interactions. Drug Development Research 66 (2006) 19-24
29. Lin J.H., and Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clinical Pharmacokinetics 35 (1998) 361-390
30. Marill J., Cresteil T., Lanotte M., and Chabot G.G. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Molecular Pharmacology 58 (2000) 1341-1348
31. Moerman D.E. Agreement and meaning: rethinking consensus analysis. Journal of Ethnopharmacology 112 (2007) 451-460
32. Sarkis A., Lopez B., and Roman R.J. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Current Opinion in Nephrology and Hypertension 13 (2004) 205-214
33. Scheen A.J. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clinical Pharmacokinetics 46 (2007) 93-108
34. Scheen A.J. Pharmacokinetic interactions with thiazolidinediones. Clinical Pharmacokinetics 46 (2007) 1-12
35. Schofield P., Mbugua D.M., and Pell A.N. Analysis of condensed tannins: a review. Animal Feed Science and Technology 91 (2001) 21-40
36. Schrag M.L., and Wienkers L.C. Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains. Archives of Biochemistry and Biophysics 391 (2001) 49-55
37. Scott I.M., Leduc R.I., Burt A.J., Marles R.J., Arnason J.T., and Foster B.C. The inhibition of human cytochrome P450 by ethanol extracts of north American botanicals. Pharmaceutical Biology 44 (2006) 315-327
38. Siest G., Jeannesson E., and Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clinica Chimica Acta 381 (2007) 26-31
39. Spence J.D. Metabolism of fibric acid derivatives [1]. Clinical Pharmacokinetics 34 (1998) 419-420
40. Spoor D.C.A., Martineau L.C., Leduc C., Benhaddou-Andaloussi A., Meddah B., Harris C., et al. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential. Canadian Journal of Physiology and Pharmacology 84 (2006) 847-858
41. Totah R.A., and Rettie A.E. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical Pharmacology and Therapeutics 77 (2005) 341-352
42. Triplitt C. Drug interactions of medications commonly used in diabetes. Diabetes Spectrum 19 (2006) 202-211
43. Wang Z., Hall S.D., Maya J.F., Li L., Asghar A., and Gorski J.C. Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans. British Journal of Clinical Pharmacology 55 (2003) 77-85
44. Xu H., Williams K.M., Liauw W.S., Murray M., Day R.O., and McLachlan A.J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. British Journal of Pharmacology 153 (2008) 1579-1586
45. Zeldin D.C., Moomaw C.R., Jesse N., Tomer K.B., Beetham J., Hammock B.D., et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Archives of Biochemistry and Biophysics 330 (1996) 87-96
46. Zhou J., and Shephard E.A. Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutation Research-Reviews in Mutation Research 612 (2006) 165-171
47. Zhou S., Gao Y., Jiang W., Huang M., Xu A., and Paxton J.W. Interactions of herbs with cytochrome P450. Drug Metabolism Reviews 35 (2003) 35-98
48. Zou L., Harkey M.R., and Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sciences 71 (2002) 1579-1589